JPH03191779A - Propagation accelerator for lactobacillus bifidus - Google Patents
Propagation accelerator for lactobacillus bifidusInfo
- Publication number
- JPH03191779A JPH03191779A JP33215889A JP33215889A JPH03191779A JP H03191779 A JPH03191779 A JP H03191779A JP 33215889 A JP33215889 A JP 33215889A JP 33215889 A JP33215889 A JP 33215889A JP H03191779 A JPH03191779 A JP H03191779A
- Authority
- JP
- Japan
- Prior art keywords
- mevalonic acid
- bifidobacteria
- growth
- weight
- lactobacillus bifidus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940068140 lactobacillus bifidus Drugs 0.000 title abstract 7
- 241000186000 Bifidobacterium Species 0.000 claims abstract description 74
- KJTLQQUUPVSXIM-ZCFIWIBFSA-N (R)-mevalonic acid Chemical compound OCC[C@](O)(C)CC(O)=O KJTLQQUUPVSXIM-ZCFIWIBFSA-N 0.000 claims abstract description 41
- KJTLQQUUPVSXIM-UHFFFAOYSA-N DL-mevalonic acid Natural products OCCC(O)(C)CC(O)=O KJTLQQUUPVSXIM-UHFFFAOYSA-N 0.000 claims abstract description 41
- 239000007952 growth promoter Substances 0.000 claims description 28
- 235000013305 food Nutrition 0.000 abstract description 14
- 239000000126 substance Substances 0.000 abstract description 14
- 239000007788 liquid Substances 0.000 abstract description 7
- 239000000796 flavoring agent Substances 0.000 abstract description 5
- 235000019634 flavors Nutrition 0.000 abstract description 5
- 244000005700 microbiome Species 0.000 abstract description 4
- 241001465754 Metazoa Species 0.000 abstract description 2
- 235000013322 soy milk Nutrition 0.000 abstract description 2
- 235000013618 yogurt Nutrition 0.000 abstract description 2
- 235000020247 cow milk Nutrition 0.000 abstract 1
- 239000000284 extract Substances 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- 241000894006 Bacteria Species 0.000 description 12
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 12
- 230000001737 promoting effect Effects 0.000 description 11
- 240000002319 Citrus sinensis Species 0.000 description 10
- 235000005976 Citrus sinensis Nutrition 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 230000002195 synergetic effect Effects 0.000 description 8
- DJWYOLJPSHDSAL-UHFFFAOYSA-N Pantethine Natural products OCC(C)(C)C(O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)C(O)C(C)(C)CO DJWYOLJPSHDSAL-UHFFFAOYSA-N 0.000 description 7
- DJWYOLJPSHDSAL-ROUUACIJSA-N pantethine Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO DJWYOLJPSHDSAL-ROUUACIJSA-N 0.000 description 7
- 229960000903 pantethine Drugs 0.000 description 7
- 235000008975 pantethine Nutrition 0.000 description 7
- 239000011581 pantethine Substances 0.000 description 7
- 239000004310 lactic acid Substances 0.000 description 6
- 235000014655 lactic acid Nutrition 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 5
- 229940008396 carrot extract Drugs 0.000 description 5
- 235000020971 citrus fruits Nutrition 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical group O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 235000015140 cultured milk Nutrition 0.000 description 4
- 235000013365 dairy product Nutrition 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 229920001542 oligosaccharide Polymers 0.000 description 4
- 150000002482 oligosaccharides Chemical class 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- 241000186660 Lactobacillus Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 235000015203 fruit juice Nutrition 0.000 description 3
- 229940039696 lactobacillus Drugs 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 2
- 229960000511 lactulose Drugs 0.000 description 2
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- 244000247812 Amorphophallus rivieri Species 0.000 description 1
- 235000001206 Amorphophallus rivieri Nutrition 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 241001672694 Citrus reticulata Species 0.000 description 1
- 241000555678 Citrus unshiu Species 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- 101000993347 Gallus gallus Ciliary neurotrophic factor Proteins 0.000 description 1
- 229920002752 Konjac Polymers 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 235000020299 breve Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000012888 dietary physiology Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000000252 konjac Substances 0.000 description 1
- 235000010485 konjac Nutrition 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 235000020138 yakult Nutrition 0.000 description 1
Abstract
Description
【発明の詳細な説明】
［産業上の利用分野］
本発明は、ビフィズス菌増殖促進剤に関し、特にはメバ
ロン酸からなるビフィズス菌増殖促進剤に関する。DETAILED DESCRIPTION OF THE INVENTION [Industrial Application Field] The present invention relates to a bifidobacteria growth promoter, and particularly to a bifidobacterium growth promoter comprising mevalonic acid.
［従来の技術］
ビフィズス菌は、母乳栄養児の腸内で特異的に優勢に存
在し、乳児の感染防止と栄養生理の面から重要視されて
きたが、近年になって成人から老人に到るまで広く分布
していることが明らかになり、ヒトにとって有益な種々
の役割を果たしていることが知られるようになった。そ
して、ヒトの健康管理の面から腸内のビフィズス菌を優
勢に維持しようとする試みが行われるようになり、ビフ
ィズス菌を添加した乳製品やビフィズス菌の生菌製剤が
市販されている。[Prior art] Bifidobacteria are uniquely predominant in the intestines of breast-fed infants, and have been regarded as important from the perspective of preventing infection in infants and nutritional physiology. It has become clear that they are widely distributed, and it has come to be known that they play a variety of roles that are beneficial to humans. From the perspective of human health management, attempts have been made to maintain a predominance of bifidobacteria in the intestines, and dairy products containing bifidobacteria and live bifidobacteria preparations are now commercially available.
また、一方では、ビフィズス菌の増殖を促進する物質が
見い出され、これをビフィズス菌とともに、または単独
で乳製品などに添加したり、ヒトに投与する試みが行わ
れている。On the other hand, substances that promote the growth of bifidobacteria have been discovered, and attempts are being made to add them to dairy products together with bifidobacteria or alone, or to administer them to humans.
ビフィズス菌の増殖を促進することが従来から知られて
いる物質としては、Ｎ−アセチルグルコサミン、ニンジ
ン抽出液に含まれるパンテチン、ラクチュロース、ラフ
ィノース（「ビフィズス菌」、株式会社ヤクルト本社、
１９７９年）、フラクトオリゴ糖、大豆オリゴ糖、コン
ニャクオリゴ糖（「理研腸内フローラシンポジウム４、
腸内フローラと食物因子」、学会出版センター、１９８
４年）、その他酵母エキス、ペプトンなどを挙げること
ができる。なお、本出願人は、柑橘類の果実にビフィズ
ス菌増殖活性物質が含まれていることを見いだし、別途
特許出願している（特願平１−９４９２８号）。Substances that have been known to promote the growth of bifidobacteria include N-acetylglucosamine, pantethine contained in carrot extract, lactulose, raffinose ("bifidobacteria", Yakult Honsha Co., Ltd.),
1979), fructooligosaccharides, soybean oligosaccharides, konjac oligosaccharides (RIKEN Intestinal Flora Symposium 4,
“Intestinal flora and food factors”, Gakkai Publishing Center, 198
4 years), yeast extract, peptone, etc. The present applicant has discovered that citrus fruits contain a substance that promotes the growth of bifidobacteria, and has filed a separate patent application (Japanese Patent Application No. 1-94928).
［発明が解決しようとする課題］
前記の公知のビフィズス菌増殖促進物質においては、ビ
フィズス菌の増殖促進効果が不十分であったり、その製
造方法が煩雑であったり、あるいは高価である等の欠点
があった。また、酵母エキスやペプトンなどを食品（例
えば発酵乳）の製造に利用する場合には、食品の風味を
損ない嗜好性の低下を招く欠点があった。[Problems to be Solved by the Invention] The above-mentioned known bifidobacteria growth-promoting substances have drawbacks such as insufficient bifidobacterium growth-promoting effects, complicated manufacturing methods, and high prices. was there. Further, when yeast extract, peptone, etc. are used in the production of foods (for example, fermented milk), there is a drawback that the flavor of the food is impaired and palatability is lowered.
本発明者は、前記の問題点を解決すべくビフィズス菌の
増殖促進物質について鋭意検討したところ、メバロン酸
にビフィズス菌増殖促進作用があり、しかも、ビフィズ
ス菌含有食品に利用しても食品の風味を損なわないこと
を見い出した０本発明は、この知見に基づくものである
。In order to solve the above-mentioned problems, the inventors of the present invention conducted extensive studies on substances that promote the growth of bifidobacteria, and found that mevalonic acid has the effect of promoting the growth of bifidobacteria. The present invention is based on this finding.
［課題を解決するための手段］
従って、本発明は、メバロン酸からなることを特徴とす
る、ビフィズス菌増殖促進剤に関するものである。[Means for Solving the Problems] Accordingly, the present invention relates to a bifidobacteria growth promoter characterized by comprising mevalonic acid.
本明細書において「ビフィズス菌」とは、ビフィドバク
テリウム属（Ｂｉｆｉｄｏｂａｃｔｅｒｉｕｍ ）に属
する微生物を意味する。As used herein, "Bifidobacterium" means a microorganism belonging to the genus Bifidobacterium.
メバロン酸は、火落ち菌（乳酸菌の１種）の増殖因子と
して発見され、種々の微生物および植物に対して成長促
進作用を有するものである。また、メバロン酸はヒトを
始めとする動植物の生体内に存在する有用な物質であり
、ヒトなどが摂取しても危険はなく、安全性の高い物質
である。Mevalonic acid was discovered as a growth factor for Hiotoshi bacteria (a type of lactic acid bacteria) and has a growth promoting effect on various microorganisms and plants. In addition, mevalonic acid is a useful substance that exists in the living bodies of animals and plants including humans, and is a highly safe substance that poses no danger even if ingested by humans.
本発明で用いることのできるメバロン酸は、天然のもの
でも、種々の方法により合成されたものでもよく、さら
に、精製されたものでも、未精製のものでもよく、特に
制限されるものではない。Mevalonic acid that can be used in the present invention may be natural or synthesized by various methods, and may be purified or unpurified, and is not particularly limited.
例えば、特開昭６３−２１６４８４号、特開昭６３−２
１６４８５号、特開昭６３−２１６４８６号または特開
昭６３−２１６４８７号の各明細書に記載されている、
微生物を利用した方法で製造することができる。また、
化学的方法で製造することもできる。For example, JP-A-63-216484, JP-A-63-2
16485, JP-A-63-216486, or JP-A-63-216487,
It can be produced by a method using microorganisms. Also,
It can also be produced by chemical methods.
本発明のビフィズス菌増殖促進剤は、ビフィズス菌１０
２〜１０６個／ｇを含有する液体に対して、０．０５〜
５．０重量％、好ましくは０．１〜３．０重量％の量で
用いる。使用量が０．０５重量％未満になると、本発明
が目的とする効果が得られない、また、５．０重量％を
超える量でメバロン酸を用いることはできるが、メバロ
ン酸使用量の増加に伴う増殖促進作用の向上がそれ以上
は認められない。The Bifidobacterium growth promoter of the present invention comprises Bifidobacterium 10
0.05~ for liquid containing 2~106 pieces/g
It is used in an amount of 5.0% by weight, preferably 0.1-3.0% by weight. If the amount used is less than 0.05% by weight, the desired effect of the present invention will not be obtained.Also, although mevalonic acid can be used in an amount exceeding 5.0% by weight, the amount of mevalonic acid used will increase. No further improvement in the proliferation-promoting effect was observed.
また、本発明のビフィズス菌増殖促進剤は、従来公知の
他のビフィズス菌増殖促進剤等と組み合わせて用いるこ
とができる０例えば、各種のオリゴ糖、ラクチュロース
、フラクトオリゴ糖、大豆オリゴ糖、あるいは柑橘類（
例えば、バレンシアオレンジ、温州みかん、夏みかん、
レモン、グレープフルーツ）の果汁または果実抽出物、
さらにニンジン抽出物（例えばパンテチン）と組み合わ
せて用いることができる。特に、前記の柑橘類の果汁ま
たは果実抽出物（例えば特願平１−９４９２８号明細書
に記載の果汁または果実抽出物）、またはニンジン抽出
物（例えばパンテチン）と組み合わせて用いると、ビフ
ィズス菌増殖促進作用が相乗的に向上する。Furthermore, the bifidobacteria growth promoter of the present invention can be used in combination with other conventionally known bifidobacterium growth promoters. For example, various oligosaccharides, lactulose, fructooligosaccharides, soybean oligosaccharides, or citrus fruit (
For example, Valencia orange, Satsuma mandarin orange, summer mandarin orange,
lemon, grapefruit) juice or fruit extract;
Furthermore, it can be used in combination with carrot extract (eg pantethine). In particular, when used in combination with the above-mentioned citrus fruit juice or fruit extract (for example, the fruit juice or fruit extract described in Japanese Patent Application No. 1-94928) or carrot extract (for example, pantethine), the growth of bifidobacteria is promoted. The effects are synergistically improved.
本発明のビフィズス菌増殖促進剤と、他のビフィズス菌
増殖促進剤とを組み合わせて用いる場合には、メバロン
酸１重量部に対して他のビフィズス菌増殖促進剤０．０
１〜１００重量部、好ましくはメバロン酸１重量部に対
して他のビフィズス菌増殖促進剤０．０３〜３０重量部
の割合で添加すればよく、両者のビフィズス菌増殖促進
剤の合計量が、ビフィズス菌１０２〜１０６個／ｇを含
有する液体に対して、０．０５〜１０．０重量％、好ま
しくは０．１〜６．０重量％の量になるようにして用い
る。使用量が０．０５重量％未満になると、相乗的な増
殖促進作用が得られない、また、１０．０重量％を超え
る量で用いることはできるが、使用量の増加に伴う相乗
作用の向上がそれ以上は認められない。When the bifidobacteria growth promoter of the present invention and another bifidobacterium growth promoter are used in combination, 0.0 part by weight of the other bifidobacterium growth promoter per 1 part by weight of mevalonic acid.
The other bifidobacteria growth promoter may be added at a ratio of 1 to 100 parts by weight, preferably 0.03 to 30 parts by weight per 1 part by weight of mevalonic acid, and the total amount of both bifidobacteria growth promoters is It is used in an amount of 0.05 to 10.0% by weight, preferably 0.1 to 6.0% by weight, based on the liquid containing 102 to 106 bifidobacteria/g. If the amount used is less than 0.05% by weight, no synergistic growth-promoting effect will be obtained, and although it can be used in an amount exceeding 10.0% by weight, the synergistic effect will improve as the amount used increases. But no more is allowed.
次に、本発明のビフィズス菌増殖促進剤を、ビフィズス
菌含有食品に添加して、ビフィズス菌を高濃度で含有す
る食品を製造することができる。Next, the bifidobacterium growth promoter of the present invention can be added to a food containing bifidobacteria to produce a food containing bifidobacteria at a high concentration.
本発明のビフィズス菌増殖促進剤は、食品製造の任意の
工程段階で添加することができる。その他の製造条件や
保存条件などは、通常のビフィズス菌含有食品について
の条件と同じでよい。The bifidobacteria growth promoter of the present invention can be added at any stage of food production. Other manufacturing conditions, storage conditions, etc. may be the same as those for normal bifidobacteria-containing foods.
本発明のビフィズス菌増殖促進剤は、ビフィズス菌を含
有する任意の食品に添加することができる。具体例とし
ては、乳製品、特に液状乳製品（例えば牛乳またはヨー
グルト）、飲料例えば豆乳等を挙げることができる。The bifidobacterium growth promoter of the present invention can be added to any food containing bifidobacteria. Specific examples include dairy products, in particular liquid dairy products (eg milk or yoghurt), beverages such as soy milk and the like.
本発明のビフィズス菌増殖促進剤は、ビフィズス菌１０
２〜１０６個／ｇ（好ましくは１０３〜１０５個／ｇ）
を含有する食品に対して、０．０５〜５．０重量％、好
ましくは０．１〜３．０重量％の量で用いる。使用量が
０．０５重量％未満になると、本発明が目的とする効果
が得られない、また、５．０重量％を超える量でメバロ
ン酸を用いることはできるが、メバロン酸使用量の増加
に伴う増殖促進作用の向上がそれ以上は認められない。The Bifidobacterium growth promoter of the present invention comprises Bifidobacterium 10
2 to 106 pieces/g (preferably 103 to 105 pieces/g)
It is used in an amount of 0.05 to 5.0% by weight, preferably 0.1 to 3.0% by weight, based on the food containing. If the amount used is less than 0.05% by weight, the desired effect of the present invention will not be obtained.Also, although mevalonic acid can be used in an amount exceeding 5.0% by weight, the amount of mevalonic acid used will increase. No further improvement in the proliferation-promoting effect was observed.
また、本発明のビフィズス菌増殖促進剤と、他のビフィ
ズス菌増殖促進剤とを組み合わせて用いてもよく、その
場合には、メバロン酸１重量部に対して他のビフィズス
菌増殖促進剤０．０１〜１００重量部、好ましくはメバ
ロン酸１重量部に対して他のビフィズス菌増殖促進剤０
．０３〜３０重量部の割合で添加すればよく、両者のビ
フィズス菌増殖促進剤の合計量が、ビフィズス菌１０２
〜１０６個／ｇ（好ましくは１０３〜１０５個／ｇ）を
含有する食品に対して、０．０５〜１０．０重量％、好
ましくは０．１〜６．０重量％の量になるようにして用
いる。使用量が０．０５重量％未満になると、相乗的な
増殖促進作用が得られない、また、１０．０重量％を超
える量で用いることはできるが、使用量の増加に伴う相
乗作用の向上がそれ以上は認められない。Furthermore, the bifidobacterium growth promoter of the present invention and other bifidobacterium growth promoters may be used in combination; in that case, 0.00% of the other bifidobacterium growth promoter per 1 part by weight of mevalonic acid. 01 to 100 parts by weight, preferably 0 parts by weight of other bifidobacteria growth promoters per 1 part by weight of mevalonic acid.
．． 03 to 30 parts by weight, and the total amount of both Bifidobacteria growth promoters is Bifidobacterium 102.
The amount should be 0.05 to 10.0% by weight, preferably 0.1 to 6.0% by weight for foods containing ~106 pieces/g (preferably 103 to 105 pieces/g). used. If the amount used is less than 0.05% by weight, no synergistic growth-promoting effect will be obtained, and although it can be used in an amount exceeding 10.0% by weight, the synergistic effect will improve as the amount used increases. But no more is allowed.
本発明のビフィズス菌増殖促進剤を、錠剤、カプセル剤
、粉体または液体などの剤形の製剤として、直接経口投
与して、腸内のビフィズス菌の増殖を促進することがで
きる。The bifidobacterium growth promoter of the present invention can be directly orally administered in the form of a tablet, capsule, powder, or liquid to promote the growth of bifidobacteria in the intestine.
本発明のビフィズス菌増殖促進剤を構成するメバロン酸
は、ラクトバシルス属（Ｌａｃｔｏｂａｃｉｌｌｕｓ
）に属する微生物、特に乳酸菌（Ｌａｃｔｏｂａｃｉｌ
ｌｕｓａｃｉｄｏｐｈｉｌｕｓ）の増殖を促進する作用
も有している。Mevalonic acid constituting the bifidobacteria growth promoter of the present invention is a compound of the genus Lactobacillus.
), especially lactic acid bacteria (Lactobacillus
It also has the effect of promoting the proliferation of S. lusacidophilus.
［実施例］
以下、実施例によって本発明を更に具体的に説明するが
、これらは本発明の範囲を限定するものではない。[Examples] Hereinafter, the present invention will be explained in more detail with reference to Examples, but these are not intended to limit the scope of the present invention.
天琵■上
特開昭６３−２１６４８７号公報に記載されている方法
で製造した、純度９５％のメバロン酸を、基本培地であ
るトマレリー（Ｔｏｍａｒｅｌｌｉ ）培地（Ｊ。Mevalonic acid with a purity of 95%, produced by the method described in JP-A No. 63-216487, was added to Tomarelli medium (J), which is a basic medium.
Ｂｉｏｌ、 Ｃｈｅｍ、、１８１．８７９．１９４９年
）に、０．３重量％、３．０重量％および無添加（対照
用）となるように添加した後、光間らの方法（Ａｇｒｉ
ｃ、 Ｂｉｏｌ、 Ｃｈｅｍ、４８．２１５９．１９８
４年）に従い、培地１ｇあたりビフィズス菌（Ｂｉｆ’
ｉｄｏ−ｂａｃｔｅｒｉｕｍ ｂｒｅｖｅ ｂｓ４６
） ２ Ｘ １０５個程度を３７℃で２４時間培養した
。菌が増殖すると培地の濁度が上昇するので、菌の増殖
度は、培地の濁度（５５０ｎｍにおける吸光度）の上昇
を測定して求めた。第１表に示した結果から明らかなよ
うに、メバロン酸はビフィズス菌に対して増殖促進効果
を示した。Biol.
c, Biol, Chem, 48.2159.198
Bifidobacterium (Bif') per gram of medium.
ido-bacterium breve bs46
) About 2 x 105 cells were cultured at 37°C for 24 hours. Since the turbidity of the medium increases when bacteria proliferate, the degree of bacterial growth was determined by measuring the increase in turbidity (absorbance at 550 nm) of the medium. As is clear from the results shown in Table 1, mevalonic acid showed a growth promoting effect on Bifidobacterium.
第１表 ※・・・培養開始時を０とする。Table 1 *...The time at the start of culture is set to 0.
実施田λ
実施例１で用いたメバロン酸０．３重量％を添加し、実
施例１と同様にして、ビフィズス菌７株について、増殖
促進効果を調べた。対照用としてメバロン酸無添加の場
合も調べた。EXAMPLE λ 0.3% by weight of mevalonic acid used in Example 1 was added, and in the same manner as in Example 1, the growth promoting effect was investigated for 7 strains of Bifidobacterium. As a control, a case without the addition of mevalonic acid was also investigated.
第２表に示した結果から明らかなように、メバロン酸は
ビフィズス菌に対して増殖促進効果を示した。As is clear from the results shown in Table 2, mevalonic acid showed a growth promoting effect on Bifidobacterium.
［以下余白］
第２表
実施例１で用いたメバロン酸を、トマレリー培地に０．
６重量％となるように添加し、ビフィズス菌（Ｂｆｆｉ
ｄｏｂａｃｔｅｒｉｕｍ ａｄｏｌｅｓｃｅｎｔｉｓ
Ａ ２０５−１４）、乳酸菌（Ｌａｃｔｏｂａｃｉ
ｌｌｕｓ ａｃｉｄｏｐｈｉｌｕｓ Ｌ−５４）およ
び大腸菌（Ｅ、ｃｏｌｉ Ｉ Ｆ Ｏ３３０１）を実
施例１と同様に３７℃で２４時間培養した。[Margins below] Table 2 Mevalonic acid used in Example 1 was added to tomarelli medium at 0.00%.
Bifidobacterium (Bffi) was added to give a concentration of 6% by weight.
dobacterium adolescentis
A 205-14), lactic acid bacteria (Lactobacillus
Ilus acidophilus L-54) and Escherichia coli (E. coli I F O3301) were cultured at 37° C. for 24 hours in the same manner as in Example 1.
対照用として、メバロン酸無添加の場合も同様に培養し
た。As a control, the cells were cultured in the same manner without the addition of mevalonic acid.
培養終了後、ビフィズス菌、乳酸菌および大腸菌の培養
液のそれぞれ１部分を、それぞれビーエル（ＢＬ）寒天
培地、ブリックス（Ｂｒｉｇｇｓ）寒天培地およびディ
ーエイチェル（ＤＨＬ）寒天培地に塗布し、ビフィズス
菌については、炭酸ガス加スチールウール法嫌気性条件
下において３７℃で４８時間、乳酸菌については、炭酸
ガス置換微好気性条件下において３７℃で４８時間、そ
して大腸菌については、好気性条件下において３７℃で
２４時間それぞれ培養した後、各培地の菌数を計数した
。After culturing, one portion of each of the cultures of Bifidobacterium, Lactic Acid Bacteria, and E. coli was applied to BL agar, Briggs agar, and DHL agar, respectively. , carbonated steel wool method under anaerobic conditions at 37°C for 48 hours; for lactic acid bacteria, under carbon dioxide exchanged microaerobic conditions at 37°C for 48 hours; and for Escherichia coli at 37°C under aerobic conditions. After culturing for 24 hours, the number of bacteria in each medium was counted.
また、それぞれの菌の培養液の濁度も測定した。In addition, the turbidity of the culture solution of each bacteria was also measured.
第３表に示した結果から明らかなように、メバロン酸は
、ビフィズス菌の生菌数を約２５倍に増加させ、増加促
進効果を示した。また、乳酸菌の生菌数も約１４倍に増
加させたのに対して、有害菌である大腸菌に対しては増
殖を促進しなかった。As is clear from the results shown in Table 3, mevalonic acid increased the number of viable Bifidobacterium bacteria by approximately 25 times, exhibiting an increase-promoting effect. Furthermore, while the number of viable lactic acid bacteria increased approximately 14 times, it did not promote the growth of E. coli, which is a harmful bacterium.
［以下余白コ 第３表 ※・・・培地１ｍｌ当たりの生菌数の対数値を示す。[Margin below] Table 3 *: Indicates the logarithm of the number of viable bacteria per ml of culture medium.
去施泗ま
ビフィズス菌増殖促進物質として、メバロン酸（実施例
１で用いたもの）、バレンシアオレンジ抽出物、および
メバロン酸とバレンシアオレンジ抽出物との混合物を用
いた。Mevalonic acid (used in Example 1), Valencia orange extract, and a mixture of mevalonic acid and Valencia orange extract were used as the Bifidobacterium growth promoting substances.
バレンシアオレンジ抽出物の調製は以下の通りに実施し
た。バレンシアオレンジを良く水洗した後、剥皮し、果
皮（乾燥重量１００ｇ）をディスクミルで粉砕した後、
粉砕物から６０℃の温水２リツトルで１時間攪拌しなが
ら抽出した。これを枦遇し、炉液をロータリーエバポレ
ータで濃縮し、真空乾燥機で乾燥して、果皮温水抽出物
（約５０ｇ）を得た。一方、果肉部分をミキサーにかけ
、沢過した後、炉液（果汁）を得た。こうして得られた
果皮温水抽出物と果汁との混合物をバレンシアオレンジ
抽出物として用いた。Preparation of Valencia orange extract was performed as follows. After washing Valencia oranges thoroughly with water, peeling them and crushing the peel (dry weight 100g) with a disc mill,
The pulverized product was extracted with 2 liters of 60°C warm water for 1 hour while stirring. Taking this into consideration, the furnace liquid was concentrated using a rotary evaporator and dried using a vacuum drier to obtain a hot water extract of the pericarp (approximately 50 g). On the other hand, the pulp part was placed in a mixer and filtered to obtain a pulp (fruit juice). The mixture of the peel warm water extract and fruit juice thus obtained was used as a Valencia orange extract.
ビフィズス菌増殖促進物質を、それぞれ、基礎培地であ
るトマレリー培地に０．６重量％となるように添加し、
実施例１と同様にして培養した。Bifidobacterium growth-promoting substances are added to a basic medium, Tomarelli medium, at a concentration of 0.6% by weight,
Culture was carried out in the same manner as in Example 1.
メバロン酸とバレンシアオレンジ抽出物との混合物の場
合は、バレンシアオレンジ抽出物０．３重量％を添加し
てから、メバロン酸０．３重量％を添加して、合計０．
６重量％とじた。For a mixture of mevalonic acid and Valencia orange extract, add 0.3% by weight of Valencia orange extract, then add 0.3% by weight of mevalonic acid, for a total of 0.3% by weight of mevalonic acid.
It was bound at 6% by weight.
菌の増殖は、培地の濁度（５５０ｎｍにおける吸光度）
の上昇を測定して求めた。第４表に示す結果から明らか
なように、メバロン酸およびオレンジ抽出物は、各々ビ
フィズス菌に対して増殖促進効果を示した。また、両者
の混合物は相乗効果を示した。Bacterial growth is determined by the turbidity of the medium (absorbance at 550 nm)
This was determined by measuring the increase in As is clear from the results shown in Table 4, mevalonic acid and orange extract each showed a growth promoting effect on Bifidobacterium. Moreover, the mixture of both showed a synergistic effect.
第４表
第５表
ビフィズス菌増殖促進物質として、メバロン酸（実施例
１で用いたもの）およびパンテチンを用いて、２種類の
ビフィズス菌、即ちＢ、１ｏｎｇｕｍ ａＥ１９４ｂと
、Ｂ、１ｎｆａｎｔｉｓ ３０１２７１−１８−４に対
して、実施例４と同様に、ビフィズス菌増殖促進活性を
調べな。Table 4 Table 5 Two types of bifidobacteria, namely B, 1ongum aE194b and B, 1nfantis 301271-18-, were grown using mevalonic acid (used in Example 1) and pantethine as bifidobacteria growth promoting substances. 4, the bifidobacteria growth promoting activity was examined in the same manner as in Example 4.
第５表に示す結果から明らかなように、メバロン酸は、
ビフィズス菌に対してパンテチンと同様のまたはより優
れた増殖促進効果を示しな、また、両者の混合物は相乗
効果を示した。As is clear from the results shown in Table 5, mevalonic acid is
It did not show similar or better growth-promoting effects than pantethine on Bifidobacteria, and the mixture of both showed a synergistic effect.
脱脂粉乳１２重量％を含有する蒸留水に、ビフィズス菌
増殖促進物質０，３重量％を添加し、さらに２種類のビ
フィズス菌（Ｂ、 ａｄｏｌｅｓｃｅｎｔｉｓ Ｅ １
９４、およびＢ、１ｏｎｇｕｍ Ｅ １９４）をそれぞ
れ１ｇ当たり約２×１０５個添加し、３７°Ｃの炭酸ガ
ス中に２４時間放置し、発酵乳を得た。この発酵乳の風
味を確認した後、０．ＩＮ水酸化ナトリウムで滴定する
ことにより、ビフィズス菌の増加酸度を測定した。To distilled water containing 12% by weight of skim milk powder, 0.3% by weight of a bifidobacteria growth promoting substance was added, and two types of bifidobacteria (B, adolescentis E 1
94, and B, 1 ongum E 194) were added thereto at about 2 x 105 pieces per gram, and the mixture was left in carbon dioxide gas at 37°C for 24 hours to obtain fermented milk. After checking the flavor of this fermented milk, 0. The increased acidity of Bifidobacterium was determined by titration with IN sodium hydroxide.
ビフィズス菌増殖促進物質として、メバロン酸（実施例
１で用いたもの）、メバロン酸とバレンシアオレンジ抽
出物（実施例４で得られたもの）との混合物（１対１混
合物）、およびパンテチン（比較用）を用いた。Bifidobacteria growth-promoting substances include mevalonic acid (used in Example 1), a mixture (1:1 mixture) of mevalonic acid and Valencia orange extract (obtained in Example 4), and pantethine (comparison). ) was used.
第６表に示す結果から明らかなように、メバロン酸は、
ビフィズス菌に対してパンテチンよりも優れた増殖促進
効果を示した。また、メバロン酸とバレンシアオレンジ
抽出物との混合物は相乗効果を示した。なお、発酵乳の
風味は良好であった。As is clear from the results shown in Table 6, mevalonic acid is
It showed a better growth-promoting effect than pantethine on bifidobacteria. Also, a mixture of mevalonic acid and Valencia orange extract showed a synergistic effect. In addition, the flavor of the fermented milk was good.
［以下余白］
第６表
［発明の効果］
本発明のビフィズス菌増殖促進剤は、食品内や腸内のビ
フィズス菌の増殖を促進する作用がある。[Margins below] Table 6 [Effects of the Invention] The Bifidobacterium growth promoter of the present invention has the effect of promoting the growth of Bifidobacteria in foods and intestines.
また、柑橘類の果実抽出物またはニンジン抽出物と併用
すると相乗効果を示す、さらに、本発明のビフィズス菌
増殖促進剤は、食品の風味を損なうことがない。Furthermore, the bifidobacteria growth promoter of the present invention exhibits a synergistic effect when used in combination with a citrus fruit extract or a carrot extract.Furthermore, the bifidobacteria growth promoter of the present invention does not impair the flavor of foods.
本発明をビフィズス菌増殖促進剤に関して説明したが、
本発明は、以下の態様を含むものである。Although the present invention has been described in relation to a bifidobacteria growth promoter,
The present invention includes the following aspects.
（１）メバロン酸と柑橘類の果実抽出物またはニンジン
抽出物とからなることを特徴とする、ビフィズス菌増殖
促進剤組成物。(1) A bifidobacteria growth promoter composition comprising mevalonic acid and a citrus fruit extract or a carrot extract.
Claims (1)
殖促進剤。A bifidobacteria growth promoter characterized by consisting of mevalonic acid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP33215889A JP2876541B2 (en) | 1989-12-21 | 1989-12-21 | Bifidobacterium growth promoter |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP33215889A JP2876541B2 (en) | 1989-12-21 | 1989-12-21 | Bifidobacterium growth promoter |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH03191779A true JPH03191779A (en) | 1991-08-21 |
| JP2876541B2 JP2876541B2 (en) | 1999-03-31 |
Family
ID=18251801
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP33215889A Expired - Fee Related JP2876541B2 (en) | 1989-12-21 | 1989-12-21 | Bifidobacterium growth promoter |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2876541B2 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994009650A1 (en) * | 1992-10-27 | 1994-05-11 | Fujisawa Pharmaceutical Co., Ltd. | Bifidobacterium growth promoter |
| WO2002045732A1 (en) * | 2000-12-05 | 2002-06-13 | Kabushiki Kaisha Yakult Honsha | Proliferation promoters for enteric bifidobacteria |
| JP2002179565A (en) * | 2000-12-15 | 2002-06-26 | Asahi Denka Kogyo Kk | Histamine release inhibitor |
| JP2002238499A (en) * | 2001-02-14 | 2002-08-27 | Asahi Denka Kogyo Kk | Therapeutic agent for hypertriglyceridemia |
-
1989
- 1989-12-21 JP JP33215889A patent/JP2876541B2/en not_active Expired - Fee Related
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994009650A1 (en) * | 1992-10-27 | 1994-05-11 | Fujisawa Pharmaceutical Co., Ltd. | Bifidobacterium growth promoter |
| WO2002045732A1 (en) * | 2000-12-05 | 2002-06-13 | Kabushiki Kaisha Yakult Honsha | Proliferation promoters for enteric bifidobacteria |
| JP2002179565A (en) * | 2000-12-15 | 2002-06-26 | Asahi Denka Kogyo Kk | Histamine release inhibitor |
| JP2002238499A (en) * | 2001-02-14 | 2002-08-27 | Asahi Denka Kogyo Kk | Therapeutic agent for hypertriglyceridemia |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2876541B2 (en) | 1999-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU709155B2 (en) | Compositions and methods for human gastrointestinal health | |
| Beheshtipour et al. | Supplementation of Spirulina platensis and Chlorella vulgaris algae into probiotic fermented milks | |
| US4187321A (en) | Method for producing foods and drinks containing bifidobacteria | |
| US6241983B1 (en) | Bacteria-and fiber-containing composition for human gastrointestinal health | |
| HU228050B1 (en) | Strain of bacteria of the species lactobacillus paracasei subsp. paracasei, composition thereof for use in food and product containing said strain | |
| JPH10286078A (en) | Composition for food containing freeze-dried live lactic acid bacterium | |
| JP2005013211A (en) | Lactobacillus-containing food composition | |
| CN105559087A (en) | Probiotic product containing sialic acid and preparation method of probiotic product | |
| RU2203946C1 (en) | Strain of bacterium lactobacillus acidophilus nv ep 317/402-x "balans-narine" used for preparing antigastritis and antiulcerous fermented-milk product | |
| JP4698927B2 (en) | Growth promoter of intestinal Bifidobacterium | |
| JPH03191779A (en) | Propagation accelerator for lactobacillus bifidus | |
| US20030077255A1 (en) | Compositions of bacteria and alpha-lactalbumin and uses thereof | |
| RU2257408C1 (en) | Curative-prophylactic biopreparation based on dry biomass of bifidum bacteria and lactic acid bacteria, biologically active food supplement based on dry biomass of bifidum bacteria and lactic acid bacteria, dry biomass of bifidum bacteria and lactic acid bacteria and method for its preparing | |
| AU742479B2 (en) | Compositions and methods for human gastrointestinal health | |
| JPH0723777A (en) | Bifidus bacteria proliferation promoting agent originated from papaya | |
| JPS61239873A (en) | Production of drink containing bifidobacterium | |
| RU2225438C2 (en) | Consortium of microorganisms mbi-4 consisting of bifidobacterium bifidum b-2, bifidobacterium infantis bi-7, bifidobacterium longum bl-5, bifidobacterium adolescentis mc-42 used for preparing fermented-milk foodstuffs | |
| Khiralla et al. | The role of fermented soymilk with potential probiotic properties in the treatment of diarrhea in young rats | |
| RU2236241C1 (en) | Fermented composition for recovery natural digestive tract microflora | |
| KR20040070688A (en) | Composition comprising microorganism having lipid metabolism-improving activity for prevention and treatement of geriatric diseases and the use thereof | |
| JP2017143799A (en) | Fermented milk food and drink | |
| IE990033A1 (en) | Bifidobacterium longum infantis in the treatment of inflammatory bowel disease | |
| JP2889270B2 (en) | Bifidobacterium growth promoter | |
| Vorobjeva et al. | Economic and medical applications | |
| RU2264451C2 (en) | Biopreparation useful in prophylaxis and treatment of dysbacteriosis and infective diseases of gastrointenstinal tract in children of 3 months - 3 years old |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080122 Year of fee payment: 9 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090122 Year of fee payment: 10 |
|
| LAPS | Cancellation because of no payment of annual fees |